Alnylam drives Intellia, Ionis higher with amyloidosis data; BridgeBio slips
Shidlovski/iStock via Getty Images


Alnylam Pharmaceuticals (ALNY) made headlines across the biotech space on Wednesday after the RNAi therapeutics company announced that its ATTR amyloidosis therapy patisiran met the main goal in a Phase 3 trial.

The much-awaited data readout propelled Alnylam (ALNY) ~55% higher, sparking a rally in the shares of its rivals focused on similar drugs.

Notable gainers include Intellia Therapeutics (NASDAQ:NTLA) and Ionis Pharmaceuticals (IONS), both of which are advancing candidates for transthyretin amyloidosis (ATTR) in partnership with major pharmaceutical companies.
In 2021, Intellia (NTLA) and its partner Regeneron (REGN), highlighted the potential of in-vivo CRISPR genome editing for the first time in humans with Phase 1 data for the CRISPR candidate NTLA-2001 in ATTR amyloidosis.

In December, Ionis (IONS) received $200M upfront after the company partnered with AstraZeneca (AZN) to develop and commercialize the subcutaneous injection eplontersen for transthyretin amyloidosis.

However, clinical-stage biotech BridgeBio Pharma (BBIO) lost ~8% in reaction to Alnylam (ALNY) data. In December, the company announced that its Phase 3 study for oral therapy acoramidis in transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) did not meet the primary endpoint.